<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comparison of COVID-19-specific treatments for children and nonpregnant* adolescents in the outpatient setting</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comparison of COVID-19-specific treatments for children and nonpregnant* adolescents in the outpatient setting</h1>
<div class="graphic"><div class="figure"><div class="ttl">Comparison of COVID-19-specific treatments for children and nonpregnant* adolescents in the outpatient setting</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="15%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Time window for initiation after symptom onset<sup>¶</sup></td> <td class="subtitle1">Age of approval/<br/> authorization</td> <td class="subtitle1">Route and duration of administration</td> <td class="subtitle1">Clinical considerations</td> </tr> <tr> <td><strong>Nirmatrelvir-ritonavir</strong></td> <td>≤5 days</td> <td> <ul> <li>≥12 years and weight ≥40 kg</li> </ul> </td> <td> <ul> <li>Oral</li> <li>5 days (twice daily)</li> </ul> </td> <td> <ul> <li>Significant drug-drug interactions with many common medications; consult a reliable prescribing reference<sup>Δ</sup> to determine if nirmatrelvir-ritonavir use is appropriate or if risk can be safely mitigated with alteration of the patient's medication regimen</li> <li>Reduce dose for eGFR 30 to 59 mL/min; avoid use in eGFR &lt;30 mL/min and in severe hepatic impairment</li> <li>Tablets cannot be chewed, broken, or crushed</li> <li>Data in children are limited</li> </ul> </td> </tr> <tr> <td><strong>Remdesivir</strong></td> <td>≤7 days</td> <td> <ul> <li>≥28 days and weight ≥3 kg</li> </ul> </td> <td> <ul> <li>Parenteral</li> <li>3 days</li> </ul> </td> <td> <ul> <li>For use in patients for whom other authorized or approved therapies are not accessible or clinically inappropriate</li> </ul> </td> </tr> <tr> <td><strong>Molnupiravir</strong></td> <td>≤5 days</td> <td> <ul> <li>≥18 years</li> </ul> </td> <td> <ul> <li>Oral</li> <li>5 days (twice daily)</li> </ul> </td> <td> <ul> <li>Avoid in pregnancy and in those at risk of pregnancy due to potential adverse effects on developing fetus</li> <li>Sexually active males with partners who may become pregnant should use effective contraception during and for 3 months after last molnupiravir dose</li> <li>Lower reported efficacy than other therapies</li> <li>Swallow capsules whole; do not open, break, or crush</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes COVID-19-specific treatments for children and nonpregnant adolescents in the outpatient setting. The decision to prescribe COVID-19 specific therapy is based upon the patient's risk for progression to severe disease and includes an assessment of risk factors (eg, underlying comorbidities) and immunization status. Refer to UpToDate content on management of COVID-19 in children for details, including doses and additional considerations. Additional information with links to fact sheets or prescribing information is available in a <a href="https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/side-by-side-overview.pdf" target="_blank">side-by-side overview</a> from the United States Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.</div><div class="graphic_footnotes"><p>COVID-19: coronavirus disease 2019; eGFR: estimated glomerular filtration rate; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p>
<p>* Refer to UpToDate content on care of pregnant patients with COVID-19.</p>
<p>¶ We encourage initiation of treatment as soon as possible after symptom onset and within the authorized/approved time windows provided in the table. The first day of symptoms is considered day 0, the next day is considered day 1, etc.</p>
Δ As an example, the <a href="https://www.fda.gov/media/158165/download" target="_blank">PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers</a> from the US Food and Drug Administration.</div><div class="graphic_reference">Reference: United States Department of Health and Human Services. Office of the Assistant Secretary for Preparedness and Response. Side-by-side overview of therapeutics authorized or approved for the prevention of COVID-19 Infection or treatment of mild-moderate COVID-19. Available at: <a href="https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx" target="_blank">aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx</a> (Accessed on June 30, 2022).</div><div id="graphicVersion">Graphic 139078 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
